Literature DB >> 7852751

Increased basal concentrations of plasma endothelin in borderline hypertension.

C E Lemne1, T Lundeberg, E Theodorsson, U de Faire.   

Abstract

BACKGROUND: There is evidence for an altered endothelial function in established hypertension but little is known about endothelial function in borderline hypertension. It has also been suggested that the early stages of hypertension are characterized by an increased sympathetic drive.
OBJECTIVE: To investigate whether alterations in endothelin, neuropeptide Y (NPY) and calcitonin gene-related peptide (CGRP) are already present in the borderline hypertensive stage.
DESIGN: A case-control study of age-matched men recruited from a population screening programme.
METHODS: Seventy-five men with stable borderline hypertension [diastolic blood pressure (DBP), 85-94 mmHg] and 75 age- and sex-matched normotensive controls (DBP < or = 80 mmHg) were investigated. Plasma samples were drawn in a standardized fashion, and extracted and analysed using competitive radio immunoassays.
RESULTS: Basal concentrations of NPY and CGRP were similar in the two groups (28.4 versus 26.7 pmol/l and 24.2 versus 21.7 pmol/l, respectively). Basal concentrations of endothelin were significantly higher in the borderline hypertensive group (2.0 versus 1.5 pmol/l, P < 0.0001).
CONCLUSIONS: These results suggest that a disturbed endothelial function, represented by endothelin, could be involved in the early hypertensive processes. They also suggest that these changes could be present before the basal sympathetic/parasympathetic drive alters, warranting further research into this area.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852751

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Attenuation of contractile responses to sympathetic co-transmitters in veins from subjects with essential hypertension.

Authors:  H Lind; D Erilnge; J Brunkwall; L Edvinsson
Journal:  Clin Auton Res       Date:  1997-04       Impact factor: 4.435

Review 2.  Endothelin and its antagonists in hypertension: can we foresee the future?

Authors:  P Moreau; T J Rabelink
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

3.  Enhanced Myogenic Constriction in the SHR Preglomerular Vessels Is Mediated by Thromboxane A2 Synthesis.

Authors:  Samera Nademi; Chao Lu; Jeffrey G Dickhout
Journal:  Front Physiol       Date:  2020-07-22       Impact factor: 4.566

4.  Association of three polymorphisms in the gene coding for endothelin-1 with essential hypertension, overweight and smoking.

Authors:  Anna Vasku; Svatava Tschöplova; Jan Muzik; Miroslav Soucek; Jiri Vacha
Journal:  Exp Clin Cardiol       Date:  2002

5.  Endothelin-1 does not prime polymorphonuclear leukocytes for enhanced production of reactive oxygen metabolites.

Authors:  S Kopprasch; A Gatzweiler; M Kohl; H E Schröder
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

6.  Steroid-induced polycystic ovaries in rats: effect of electro-acupuncture on concentrations of endothelin-1 and nerve growth factor (NGF), and expression of NGF mRNA in the ovaries, the adrenal glands, and the central nervous system.

Authors:  Elisabet Stener-Victorin; Thomas Lundeberg; Stefan Cajander; Luigi Aloe; Luigi Manni; Urban Waldenström; Per Olof Janson
Journal:  Reprod Biol Endocrinol       Date:  2003-04-08       Impact factor: 5.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.